These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20942208)

  • 1. [Natural killer cell activity, lymphokine activated killer cell activity (LAK activity), and killer-helper factors (KHF)].
    Sugimoto T; Kumagai S; Hatachi S; Koshiba M
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():873-6. PubMed ID: 20942208
    [No Abstract]   [Full Text] [Related]  

  • 2. [Natural killer cell activity, activity of lymphokine-activated killer cells (LAK activity), and killer-helper factors (KHF)].
    Hatachi S; Kumagai S; Koshiba M
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():781-3. PubMed ID: 16111393
    [No Abstract]   [Full Text] [Related]  

  • 3. [Natural killer cell activity, activity of lymphokine activated killer cells (LAK activity), killer helper factor (KHF)].
    Watabe H; Abo T
    Nihon Rinsho; 1999 Nov; 57 Suppl():666-9. PubMed ID: 10635943
    [No Abstract]   [Full Text] [Related]  

  • 4. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ; Silver HK; Kong S
    Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer cells are rejected in vivo by activated natural killer cells.
    Brubaker JO; Chong KT; Welsh RM
    J Immunol; 1991 Aug; 147(4):1439-44. PubMed ID: 1869833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
    Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
    Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease of lymphokine (interleukin-2)-activated killer activity in peripheral blood after administration of natural interferon-gamma.
    Yanagawa H; Sone S; Okubo A; Fukuta K; Nishioka Y; Ogura T
    Jpn J Clin Oncol; 1990 Dec; 20(4):356-63. PubMed ID: 2126575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
    Dannemann BR; Morris VA; Araujo FG; Remington JS
    J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities.
    Komiyama A; Kawai H; Yabuhara A; Yanagisawa M; Miyagawa Y; Ota M; Hasekura H; Akabane T
    Pediatrics; 1990 Mar; 85(3):323-30. PubMed ID: 2304785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
    Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
    Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin.
    Shau H; Kim A; Golub SH
    J Leukoc Biol; 1992 Apr; 51(4):343-9. PubMed ID: 1564398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF; Hough KL; Holder WD
    Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells.
    Gunji Y; Lewis J; Gorelik E
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):663-72. PubMed ID: 2133246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
    Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depressed lymphokine-activated killer activity and analysis of the precursor cells in peripheral blood of patients with hepatocellular carcinoma.
    Shirai M; Watanabe S; Nishioka M
    Hepatogastroenterology; 1990 Oct; 37(5):465-8. PubMed ID: 2174825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociation of natural killer and lymphocyte-activated killer cell lytic activities in human CD3- large granular lymphocytes.
    Clément MV; Legros-Maida S; Soulie A; Guillet J; Sasportes M
    Eur J Immunol; 1993 Mar; 23(3):697-701. PubMed ID: 8449217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.